---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-115796"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T12:01:35.099288+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Celldex Therapeutics prices $200.5M public offering of 7.425M shares at $27.00

## Summary
- Offering of 7,425,000 shares at $27.00 per share; underwriters have 30-day option for 1,113,750 additional shares.
- Net proceeds expected ~$188.3M after discounts and expenses.
- Proceeds to fund clinical/preclinical development including barzolvolimab and bispecific antibody platform.
- Offering expected to close on or about Nov 10, 2023; Jefferies and Leerink Partners lead the underwriting.

## SEC filing metadata
- accession: 0001104659-23-115796
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000110465923115796/0001104659-23-115796-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000110465923115796/tm2330052d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-115796
- JSON: https://secwatch.observer/filing/0001104659-23-115796.json
- Plain text: https://secwatch.observer/filing/0001104659-23-115796.txt

## Key facts
- Material Agreements
  Celldex Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters (effective 2023-11-07).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters
  - Effective: 2023-11-07
  source text: On November 7, 2023, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Leerink Partners LLC (the “Representatives”), as representatives of the several underwriters named therein (the “Underwriters”), relating to the offering, issuance and sale of 7,425,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 (the “Common Stock”), at a price to the public of $27.00 per share (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/744218/000110465923115796/0001104659-23-115796-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.